Exelixis, Inc. (NASDAQ:EXEL) Stock Holdings Boosted by EULAV Asset Management

EULAV Asset Management lifted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 10.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 530,000 shares of the biotechnology company's stock after buying an additional 50,000 shares during the period. EULAV Asset Management owned approximately 0.19% of Exelixis worth $19,568,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. TD Private Client Wealth LLC lifted its stake in shares of Exelixis by 29.5% in the first quarter. TD Private Client Wealth LLC now owns 12,944 shares of the biotechnology company's stock worth $478,000 after acquiring an additional 2,950 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Exelixis by 23.9% in the first quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company's stock worth $9,159,000 after acquiring an additional 47,845 shares in the last quarter. Penserra Capital Management LLC acquired a new position in shares of Exelixis in the first quarter worth about $1,298,000. Concurrent Investment Advisors LLC acquired a new position in shares of Exelixis in the first quarter worth about $457,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Exelixis by 0.6% in the first quarter. Bank of New York Mellon Corp now owns 2,476,857 shares of the biotechnology company's stock worth $91,446,000 after acquiring an additional 15,239 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Exelixis Price Performance

EXEL stock traded down $0.25 on Tuesday, reaching $43.91. The company's stock had a trading volume of 507,038 shares, compared to its average volume of 2,497,738. Exelixis, Inc. has a 52 week low of $21.86 and a 52 week high of $49.62. The company has a market capitalization of $11.98 billion, a P/E ratio of 19.93, a price-to-earnings-growth ratio of 0.93 and a beta of 0.28. The firm has a fifty day moving average of $41.99 and a two-hundred day moving average of $37.79.

Analyst Ratings Changes

EXEL has been the topic of several recent analyst reports. HC Wainwright boosted their price target on Exelixis from $47.00 to $53.00 and gave the stock a "buy" rating in a research note on Monday, June 30th. Truist Financial reiterated a "buy" rating and issued a $55.00 price target (up previously from $43.00) on shares of Exelixis in a research note on Monday, June 23rd. Royal Bank Of Canada restated a "sector perform" rating and set a $50.00 price objective (up previously from $45.00) on shares of Exelixis in a research note on Tuesday. Morgan Stanley restated an "overweight" rating and set a $47.00 price objective (up previously from $40.00) on shares of Exelixis in a research note on Wednesday, May 14th. Finally, Stephens upgraded Exelixis from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $29.00 to $60.00 in a research note on Tuesday, June 24th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $44.11.

Insiders Place Their Bets

In related news, EVP Patrick J. Haley sold 126,383 shares of the stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $47.96, for a total value of $6,061,328.68. Following the completion of the transaction, the executive vice president directly owned 446,459 shares of the company's stock, valued at $21,412,173.64. This represents a 22.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Stelios Papadopoulos sold 36,508 shares of the stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $44.35, for a total value of $1,619,129.80. Following the completion of the transaction, the director directly owned 1,279,416 shares of the company's stock, valued at $56,742,099.60. This trade represents a 2.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 458,113 shares of company stock worth $21,024,817. 2.85% of the stock is owned by company insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.